Michael F. Mahoney
Chairman, President and Chief Executive Officer
Executive
14 yr
14 reports
Boston Scientific Corporation ·BSX
Two global P&L presidents dominate the CEO’s span
Health Care · Fortune #248 · Divisional structure · 53K employees · Marlborough, Massachusetts
View as of:
6
CEO span
↓ tighter than peers (avg 11)
3.2
Avg span
moderate
3
Max depth
3 levels
6.5 yr
Avg tenure
stable vs FY2024
67%
Internal hires
↑ above industry avg
Consolidated financials FY2025 · period end 2025-12-31 · 10-K
Revenue
$20.1B
Operating income
$3.6B
Net income
$2.9B
Total assets
$43.7B
Shares out
1.48B
Sourced from Boston Scientific Corporation DEF 14A · filed 2026-03-18 ↗ View on SEC
Interactive org chart
Boston Scientific Corporation organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
Boston Scientific is organized around two powerful global P&L presidents reporting to the CEO. This page maps the executive structure, key divisional leaders, governance context, recent leadership changes, and how the model compares with other large medtech peers.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal Jeffrey B. Mirviss departed as Executive Vice President and President, Peripheral Interventions
Retired from the company effective February 27, 2026.
Source · See change logScenario views in the chart
- Add Chief Operating Officer Introduce a COO to centralize operations and reduce the CEO’s reliance on divisional presidents.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
6 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
internal
Joseph M. Fitzgerald
Executive Vice President and Group President, Cardiovascular
Cardiovascular
8 yr
2 reports
internal
Arthur C. Butcher
Executive Vice President and Group President, MedSurg and Asia Pacific
MedSurg / APAC
9 yr
2 reports
Jonathan R. Monson
Executive Vice President and Chief Financial Officer
Finance
1 yr
3 reports
internal
Vance R. Brown
Executive Vice President, General Counsel and Corporate Secretary
Legal
6 yr
2 reports
Open Role
Chief Human Resources Officer
Human Resources
1 yr
0 reports
The pay
Executive compensation
From the most recent DEF 14A Summary Compensation Table. 1 named executive officers disclosed. Bar length scales with total compensation.
Michael F. Mahoney $23.5M
- Base salary
- $1.44M
- Stock awards
- $13.61M
- Option awards
- $3.75M
- Non-equity incentive
- $4.00M
- Pension change
- $442K
- Other
- $288K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
The businesses
How Boston Scientific Corporation divides the work
4 divisions report into the group CEO. Tile size scales with estimated headcount.
Cardiovascular
22K employees
Group President, Cardiovascular (Joseph M. Fitzgerald)
Develops and commercializes interventional cardiology and peripheral vascular therapies.
MedSurg
21K employees
Group President, MedSurg and Asia Pacific (Arthur C. Butcher)
Includes endoscopy, urology, and other minimally invasive surgical platforms.
Finance
2K employees
EVP & CFO (Jonathan R. Monson)
Manages capital allocation, financial reporting, treasury, and investor relations.
Legal & Compliance
1K employees
EVP, General Counsel (Vance R. Brown)
Oversees legal, regulatory, ethics, and corporate governance matters.
The thesis
Why this org is unusual
Two global P&L presidents — Cardiovascular and MedSurg/APAC — account for the majority of operating control at Boston Scientific.
The CEO’s span is concentrated in these two leaders, each overseeing multiple therapy-area SVPs. This reflects a classic medtech divisional model optimized for scale, regulatory specialization, and capital allocation discipline.
Corporate functions remain lean at the top. Finance and Legal are represented by single EVPs, with most operational depth pushed down into the divisions. The absence of a COO role reinforces the reliance on strong group presidents rather than centralized operations oversight.
- No COO role
- Two group presidents control most revenue
- Lean corporate center
The comparison
How Boston Scientific Corporation stacks up
Compared with large medtech peers such as Medtronic and Abbott, Boston Scientific operates with a narrower C-suite and heavier reliance on divisional P&L leaders. Medtronic typically adds a COO layer and deeper regional presidents, while Abbott maintains more segment presidents with corporate overlays. Boston …
C-suite size
Reporting depth
Boston Scientific Corporation
3 levels
Medtronic
5 levels
Abbott Laboratories
5 levels
6 levels
4 levels
Avg C-suite tenure
Boston Scientific Corporation
7 yr
Medtronic
6 yr
Abbott Laboratories
8 yr
6 yr
Has COO / Has CAIO
Boston Scientific Corporation — no COO — no CAIO
Medtronic ✓ COO — no CAIO
Abbott Laboratories — no COO — no CAIO
Current signals
What changed recently
The most significant change was the CFO transition from Daniel Brennan to Jonathan Monson in mid‑2025.
- departedJeffrey B. Mirviss Executive Vice President and President, Peripheral Interventions
Retired from the company effective February 27, 2026.
Source - newJonathan R. Monson Executive Vice President and Chief Financial Officer
Appointed CFO effective June 30, 2025.
Source - departedDaniel J. Brennan Executive Vice President and Chief Financial Officer
Retired as CFO on June 29, 2025; served as senior advisor until October 3, 2025.
Source
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-03-18
- CEO
- Michael F. Mahoney
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 6.2 yr
Leadership centered on two global operating groups.
Named executive officers (5)
- Michael F. Mahoney - CEO since 2012
- Jonathan R. Monson - CFO since 2025
- Vance R. Brown - General Counsel since 2019
- Arthur C. Butcher - Group President, MedSurg since 2016
- Joseph M. Fitzgerald - Group President, Cardiovascular since 2017
FY2024
DEF 14A filed 2025-03-20
- CEO
- Michael F. Mahoney
- CEO span
- 6
- C-suite
- 6
- Avg tenure
- 7.1 yr
Pre‑CFO transition year.
Named executive officers (5)
- Michael F. Mahoney - CEO since 2012
- Daniel J. Brennan - CFO since 2018
- Vance R. Brown - General Counsel since 2019
- Arthur C. Butcher - Group President, MedSurg since 2016
- Joseph M. Fitzgerald - Group President, Cardiovascular since 2017
FY2023
DEF 14A filed 2024-03-22
- CEO
- Michael F. Mahoney
- CEO span
- 6
- C-suite
- 6
- Avg tenure
- 7.8 yr
Stable executive team.
Named executive officers (5)
- Michael F. Mahoney - CEO since 2012
- Daniel J. Brennan - CFO since 2018
- Vance R. Brown - General Counsel since 2019
- Arthur C. Butcher - Group President, MedSurg since 2016
- Joseph M. Fitzgerald - Group President, Cardiovascular since 2017
Year-over-year changes
The primary change was a CFO succession that slightly reduced average tenure.
- CEO span: 6 → 5
- C-suite size: 6 → 5
- Avg tenure: 7.1 → 6.2 yr
- new Jonathan R. Monson - CFO (DEF 14A, 2026-03-18)
- departed Daniel J. Brennan - CFO (was CFO) (DEF 14A, 2026-03-18)
The board
Board of directors
1 directors. 0 of 1 independent (0%). Source: most recent DEF 14A.
Michael F. Mahoney
Chair Inside
Chairman, President and CEO, Boston Scientific
Frequently Asked Questions
Who is the CEO of Boston Scientific?
Michael F. Mahoney has served as Chairman, President and CEO since 2012.
What type of organizational structure does Boston Scientific use?
Boston Scientific uses a divisional structure centered on major global P&L groups.
How many direct reports does Boston Scientific's CEO have?
The CEO has six direct reports, including two group presidents and key corporate executives.
How has Boston Scientific's leadership changed recently?
The company completed a CFO transition in 2025 and saw retirements of two senior EVPs through early 2026.
Does Boston Scientific have a COO?
No, Boston Scientific does not currently have a Chief Operating Officer role.
Sources
- DEF 14A Filing, Mar 2026
- SEC EDGAR: Boston Scientific Corporation DEF 14A Proxy Statement
- SEC EDGAR: Boston Scientific Corporation 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). Boston Scientific Corporation organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/boston-scientific/MLA 9th
"Boston Scientific Corporation Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/boston-scientific/. Accessed .Chicago 17
Creately. "Boston Scientific Corporation Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/boston-scientific/.Original SEC source View on SEC ↗
Boston Scientific Corporation. DEF 14A. Filed 2026-03-18. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/885725/000088572526000025/bsx-20260318.htmPermanent URL: https://creately.com/org-chart/fortune-500/boston-scientific/ · last updated 2026-04-01